Clinical trial · Observational
A Retrospective Cohort Study: Influence of MTHFR C677T and A1298C Polymorphisms on the Survival of Pediatric Patients With Non-Hodgkin's Lymphoma
NCT04469543CI-TRIAL-00045945completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this retrospective study was to investigate the influence of methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphism on the survival of pediatric patients with Non-Hodgkin lymphoma (NHL) treated with modified NHL-BFM95 protocol in south China.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric Non-Hodgkin Lymphoma | Childhood Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- MTHFR polymorphism
Primary outcomes (2)
- measure
- Death
- timeFrame
- About six years
- description
- Overall survival time was calculated from the time of initial diagnosis to death
- measure
- Events including progression, relapse, and secondary cancer
- timeFrame
- About six years
- description
- Event-free survival (EFS) time was calculated from the time of initial diagnosis to first event.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. aged ≤ 18 years; 2. newly diagnosed as the four main categories of NHL(Burkitt's lymphoma, lymphoblastic lymphoma, anaplastic large cell lymphoma, and diffuse large B-cell lymphoma) between 2014 and 2020; 3. treated according to the modified BFM95 protocol. Exclusion Criteria: 1. aged \> 18 years; 2. not newly diagnosed as the four main categories of NHL between 2014 and 2020; 3. treated according to chemotherapeutic regimens except for the modified BFM95 protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.